UPDATE: CryoLife (CRY) Sells PerClot to Baxter for $60.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to UPDATE: CryoLife (CRY) Sells PerClot to Baxter for $60.8M
July 29, 2021 8:00 AM EDT
ATLANTA, July 29, 2021 /PRNewswire/ --Â CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. ("Baxter") (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive up to $45.8 million and Starch Medical, Inc. ("SMI") will receive up to $15.0 million. In this sale, CryoLife has transferred its PerClot product line to Baxter and SMI has agreed to transfer or extend certain rights to... More
July 29, 2021 8:00 AM EDT
Marks Baxters entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive solutions
DEERFIELD, Ill.--(BUSINESS WIRE)--
Baxter International Inc. (NYSE: BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE: CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select... More
